United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
Go back to United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2| United Therapeutics Corp (NASDAQ: UTHR) | Delayed: 538.30 +1.71 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $536.59 | 52 Week High | $164.04 | |||
| Open | $541.25 | 52 Week Low | $97.52 | |||
| Day High | $541.53 | P/E | 98.41 | |||
| Day Low | $533.49 | EPS | $5.47 | |||
| Volume | 620,875 | |||||
